Matinas BioPharma (MTNB) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights
May 10, 2021 6:30 AM EDTEnrollment continues in second cohort of EnACT study of MAT2203 (oral amphotericin b) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data from second cohort anticipated Q3 2021
MAT2501 (oral amikacin) advanced into preclinical toxicology and efficacy studies; completion of Phase 1 SAD study in healthy volunteers anticipated by end of 2021
Matinas to host virtual R&D Day on June 17, 2021 to highlight LNC platform and related programs
Data from ENHANCE-IT study of LYPDISO against Vascepa® reported in Q1 2021 support continued development of LYPDISO as a potential best-in-class... More
